ArticleAnnals of medicine2026
Steatotic liver disease subtypes and risk of hospitalization for sepsis: a nationwide cohort study.
Article in Annals of medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe recent reclassification of steatotic liver disease (SLD) into metabolic dysfunction-associated SLD (MASLD), MASLD with increased alcohol intake (MetALD), and alcohol-related liver disease (ALD) provides a clinically relevant framework for distinguishing heterogeneous etiologic subtypes. However, whether these newly defined SLD subtypes differ in their susceptibility to sepsis remains unclear. We assessed the incidence and risk of hospitalization for sepsis across the SLD spectrum in a nationwide cohort.
methodsWe conducted a retrospective cohort study using the Korean National Health Insurance Service database, including 4,389,734 adults who underwent health screening in 2012. SLD was defined as a fatty liver index (FLI) ≥30 and subtyped as MASLD, MetALD, or ALD based on cardiometabolic risk profiles and alcohol intake; FLI <30 defined the non-SLD reference group. Sepsis was identified using hospitalization claims and ICD-10 codes from 2013 to 2022. Adjusted hazard ratios (aHRs) were estimated using multivariable Cox proportional hazards models, with subgroup and sensitivity analyses.
resultsThe cohort comprised MASLD (
conclusionsAll SLD subtypes were associated with increased but distinct risks of hospitalization for sepsis, with ALD conferring the highest risk. These findings support subtype-specific risk stratification and may inform infection-prevention strategies and clinical surveillance in individuals with SLD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.